OBJECTIVE: To evaluate the health care costs of a physicianpharmacist collaborative care (PPCC) over usual care (UC) for patients at moderate (MR) or high risk (HR) of coronary heart disease with dyslipidemia. Trained community pharmacists provided advance care including monitoring of laboratory tests and lipid-lowering medication dosage adjustments. METHODS: Annual direct health care costs and incremental costs were estimated from an interim analysis of a 3-year cluster randomised controlled trial (TEAM study) evaluating the efficacy of a PPCC versus UC for patients on a statin but not at lipid targets. The mean annual costs of pharmacists' follow-up (pharmacists' training, pharmacist visits, laboratory tests), physicians' follow-up (physician visits, laboratory tests), lipid-lowering treatment (medication, pharmacists' fee), and total cost (pharmacists' follow-up, physicians' follow-up, lipid-lowering treatment) were compared between groups by t-tests. RESULTS: Geographical clusters of general practitioners (GP) and pharmacists were randomised to PPCC (GP = 41; pharmacists = 58) or UC (GP = 36; pharmacists = 46) and followed 167 patients (PPCC = 67; UC = 100). Community pharmacists can provide advance care to patients with dyslipidemia at a reasonable cost and contribute to reduce the GP workload.
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DRUG-ELUTING STENTS FROM A MEDICARE PAYER PERSPECTIVE: COST-UTILITY ANALYSIS WITH 4-YEAR CLINICAL META-ANALYSIS DATA
Bischof M 1 , Briel M 2 , Bucher HC 2 , Nordmann A 2 1 University of Basel, Basel, BS, Switzerland, 2 University Hospital Basel, Basel, BS, Switzerland OBJECTIVE: After several years of use, the cost-effectiveness question of drug-eluting stents (DES) has not been answered satisfactorily due to a limited time horizon in previous analyses. Using four year follow-up clinical data from a large metaanalysis we examined the cost-effectiveness of Cypher and Taxus stents compared to bare-metal stents with a decision analytic cost-utility model from a Medicare payer perspective.
METHODS:
We developed a five state Markov cost-utility decision analytic model. The model included the events MI, CABG and the need for a repeated percutaneous coronary intervention. Transition probabilities were directly extracted from the metaanalysis. Quality of life data was derived from the ARTS trial. Costs for the resource use (including stenting with DES and BMS) were obtained from Medicare diagnosis related groups for ten leading cardiology hospitals and a random sample of ten United States hospitals offering stenting procedures. All costs are in USD$ of the financial year 2007. Probabilistic sensitivity analysis was performed with 10,000 Monte Carlo simulations. RESULTS: Cypher stents are slightly more effective than bare metal stents with an incremental effect of 0.001 QALYs (95% CI -0.042 to 0.012 QALYs), while the Taxus stents provide -0.004 incremental QALYs (95% CI -0.064 to 0.012). DES are more costly than BMS. At a willingness to pay of $100,000/QALY, the incremental net monetary benefit (INMB) for Cypher stents is $-940 and $-1612 for Taxus stents, respecively, for the leading hospitals. Using the random sample of hospitals Cypher and Taxus stents yield an INMB of $-1146 and $-1751, respectively. The probability that DES are cost-effective ranges from 34% for Taxus stents in the random sample to 43% for Cypher stents in the leading hospitals. CONCLUSION: From a Medicare perspective, the use of drug-eluting as compared to bare metal stents is not cost-effective when implanted in unselected patients with symptomatic ischemic coronary artery disease. To determine the cost-utility of aliskiren in combination or monotherapy vs. usual care for patients with mild to moderate hypertension from the Canadian health care system perspective. METHODS: A Markov model was programmed to simulate patient flow between 17 health states (including death), different treatment lines and allowing for non-persistence. Cardiovascular disease (CVD) related outcomes were projected for over 40 years from systolic blood pressure (SBP) reductions observed in several randomized trials using risk equations from landmark studies, including the Framingham Heart Study. Patients were at low risk of CVD, based on their demographic and clinical history at baseline. The following comparisons were analyzed: aliskiren + thiazide-diuretic vs. ACEI + thiazidediuretic, ARB + thiazide-diuretic, and CCB + thiazide-diuretic, aliskiren + CCB vs. thiazide-diuretic + CCB, and aliskiren vs. ARB. Direct costs for health states and events were taken from published literature. Weighted average unit prices were obtained for each antihypertensive drug class. All costs are in 2007 CAD. The primary outcome was incremental cost per additional quality-adjusted life-year QALY. Additional outcomes included life expectancy and number of CVD-related deaths. RESULTS: Aliskiren + thiazide-diuretic was shown to be dominant vs. CCB + thiazide-diuretic, cost-effective in monotherapy vs. ARB ($1011/QALY) and cost-effective when in combination therapy with CCB vs. thiazide-diuretic + CCB ($29,813/QALY). More variability occurred when comparing aliskiren + thiazide-diuretic to ARB + thiazide-diuretic (ranging from dominance to being dominated). Based on pooled data of aliskiren vs. ARBs showing similar SBP-lowering effect, the cost impact of aliskiren is
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